drugset / Trial / NCT05729243

Cytisine for Smoking Cessation

NCT05729243

Phase 4 Completed 20 enrolled Centre for Addiction and Mental Health
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of cytisine as a smoking cessation treatment in individuals with concurrent alcohol use disorder.

Timeline

Start
2023-02-08
Primary completion
2025-12-12
Completion
2025-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytisinicline Small molecule 1.5 mg Oral